| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI improves diagnostic accuracy in medical imaging because it can process and analyze large amounts of data quickly and more precisely than humans. |
AI systems can rapidly analyze complex imaging data and detect patterns or abnormalities (such as tumors, fractures, or lesions) that may be subtle or difficult for humans to identify. This enhances diagnostic precision and reduces the workload for radiologists, allowing for quicker and more accurate medical decisions. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI can detect subtle patterns and anomalies in imaging data that may be missed by human eyes, especially under high workloads or in early-stage diseases. It also speeds up image analysis, helping radiologists process more cases in less time with greater consistency and fewer errors. |
Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again.
Esteva, A., et al. (2017). "Dermatologist-level classification of skin cancer with deep neural networks." Nature, 542(7639), 115–118. https://doi.org/10.1038/nature21056 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy is not just about knowing how to operate AI systems, but also involves understanding their limitations, interpreting their outputs correctly, and integrating them responsibly into decision-making processes. |
Davenport, T., & Kalakota, R. (2019). "The potential for AI in healthcare." Future Healthcare Journal, 6(2), 94–98. https://doi.org/10.7861/futurehosp.6-2-94 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
While factors such as trust in the technology, transparency, ease of use, training, and perceived usefulness are commonly cited as influencing how healthcare professionals accept and adopt AI, superficial elements like the color or aesthetic design of the interface do not play a significant role in their acceptance of AI tools. |
Geis, J. R., et al. (2019). "Ethics of artificial intelligence in radiology: Summary of the Joint European and North American Multisociety Statement." Insights into Imaging, 10, 101. https://doi.org/10.1186/s13244-019-0785-8 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
When respected colleagues, institutional leaders, or professional bodies support or positively engage with AI tools, it increases confidence and trust among other healthcare workers. This peer influence can encourage adoption, especially when AI is seen as a standard or valued part of clinical practice. Conversely, skepticism or resistance from influential figures may discourage others from accepting or using AI. |
Venkatesh, V., Morris, M. G., Davis, G. B., & Davis, F. D. (2003). "User acceptance of information technology: Toward a unified view." MIS Quarterly, 27(3), 425–478. (Often used in healthcare AI studies under the UTAUT model) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Many healthcare workers express concern that as AI systems become more advanced, they could potentially take over tasks traditionally performed by clinicians. such as diagnosis, treatment planning, or image interpretation. |
Saba, L., et al. (2021). "The present and future of artificial intelligence in radiology." European Journal of Radiology, 138, 109690. https://doi.org/10.1016/j.ejrad.2021.109690
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
When healthcare professionals understand the logic behind AI tools, how to interpret their outputs, and how to apply them in real-world scenarios, they are more likely to trust and adopt the technology. |
Davenport, T., & Kalakota, R. (2019). "The potential for AI in healthcare." Future Healthcare Journal, 6(2), 94–98.
Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
Healthcare professionals are more likely to accept and adopt AI tools if they are user-friendly, seamlessly fit into current clinical processes, and consistently deliver accurate, helpful results. |
Venkatesh, V., et al. (2003). UTAUT model (Unified Theory of Acceptance and Use of Technology) - often cited in studies examining technology acceptance in healthcare settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Healthcare professionals are more likely to accept AI if they believe it operates ethically. For example, if it protects patient confidentiality, avoids bias, supports informed consent, and does not compromise human oversight. |
Geis, J. R., et al. (2019). "Ethics of artificial intelligence in radiology: Summary of the Joint European and North American multisociety statement." Insights into Imaging, 10, 101. https://doi.org/10.1186/s13244-019-0785-8
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
A mixed-methods approach combines both quantitative (e.g., surveys, statistical analysis) and qualitative (e.g., interviews, focus groups) methods to gain a deeper understanding of how and why healthcare professionals accept or reject AI. |
Venkatesh, V., et al. (2003). UTAUT model.
Also aligned with principles in:
Creswell, J. W., & Plano Clark, V. L. (2017). Designing and Conducting Mixed Methods Research. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease is characterized by the degeneration of dopamine-producing neurons in the substantia nigra region of the brain. Human embryonic stem cells have the ability to differentiate into these specific neuron types, offering the potential to repair or replace damaged neural circuits. |
Takahashi, J., & Yamanaka, S. (2016). "Induced pluripotent stem cells in medicine and biology." Development, 143(13), 2184–2196. https://doi.org/10.1242/dev.140863 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
rats were used because they are immunodeficient, making them suitable for testing stem cell therapies without immune rejection. This allows researchers to accurately assess the safety and efficacy of the STEM-PD product before clinical use in humans. Additionally, these animal models help observe long-term effects and cellular responses in a real nervous system environment, providing confidence in the treatment’s safety and potential effectiveness for further development. |
Barker, R. A., Parmar, M., & Studer, L. (2017). Human stem cell-derived dopaminergic neurons in Parkinson’s disease. Nature Reviews Neuroscience, 18(2), 92–103. https://doi.org/10.1038/nrn.2016.198 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
12 months |
|
12 Months study allows researchers to monitor long-term safety, potential tumor formation, and sustained efficacy of the STEM-PD product before proceeding to human clinical trials. This extended observation period is crucial for detecting delayed adverse effects and confirming the stability of the stem cell therapy.
|
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The STEM-PD clinical trial is in the Phase I/IIa stage because this phase focuses on assessing the safety of the treatment in humans (Phase I) alongside preliminary evaluation of its efficacy (Phase IIa). |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The manufacturing process involves carefully guiding hESCs through specific developmental stages to produce the targeted type of neurons lost in Parkinson’s disease. This is done using defined culture media and growth factors to ensure consistency, purity, and safety of the final cell product suitable for transplantation. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
This long-term study showed that the transplanted cells integrated safely without causing tumors or other harmful effects, supporting the product’s safety profile before advancing to human clinical trials. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
This demonstrated that the STEM-PD product could potentially restore lost neuronal function and alleviate motor symptoms by effectively replacing damaged dopamine, producing neurons in the brain. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
LMX1A and EN1 are transcription factors indicative of midbrain dopaminergic progenitor identity. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b and SHH are signaling molecules that mimic developmental cues in the embryonic brain, promoting the specification and maturation of dopaminergic neurons. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The efficacy of the STEM-PD product was evaluated by observing whether transplanted dopaminergic progenitor cells could restore motor abilities impaired by Parkinson’s disease in rat models. Positive changes in movement and coordination demonstrated functional recovery. |
Kirkeby, A., et al. (2017). Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell, 20(1), 135–148. https://doi.org/10.1016/j.stem.2016.10.004 |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|